Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2010
10/19/2010CA2463284C Pyrimidine compounds and pharmaceutical compositions containing the compounds
10/19/2010CA2458853C Use of fucans in the treatment of adhesions, arthritis and psoriasis
10/19/2010CA2458699C Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
10/19/2010CA2456547C Process for preparing inhalable powders
10/19/2010CA2454006C Pullulan-containing powder, the process for the same and use thereof
10/19/2010CA2451422C Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
10/19/2010CA2448089C Thiolalkyl benzoic acid derivatives
10/19/2010CA2443484C Halogen-substituted quinoline derivatives and ectoparasite control agent
10/19/2010CA2439791C Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/19/2010CA2437409C Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
10/19/2010CA2437196C A composition for the treatment of heart failure comprising levosimendan and a calcium ion source and/or an intreacellular calcium increasing agent
10/19/2010CA2436589C Heterocyclic compounds and cognitive enhancers comprising the same as effective components
10/19/2010CA2436526C Heterocyclic sulfonamide inhibitors of beta amyloid production
10/19/2010CA2433417C Novel 1,2-diphenylethene derivatives for treatment of immune diseases
10/19/2010CA2429496C Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
10/19/2010CA2427282C Mixtures or organic compounds for the treatment of airway diseases
10/19/2010CA2417629C Derivatives of variolin b
10/19/2010CA2416512C Enhancement of the action of anti-infective agents
10/19/2010CA2415577C Use of cox-2 inhibitors for preventing immunodeficiency
10/19/2010CA2409743C Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
10/19/2010CA2400667C Modified nodavirus rna for gene delivery
10/19/2010CA2399840C Use of roflumilast or pumafentrine in combination with methotrexate for the treatment of arthritic diseases
10/19/2010CA2397789C Novel human kinase protein and polynucleotides encoding the same
10/19/2010CA2393158C Substituted homopiperidinyl benzimidazole analogues as fundic relaxants
10/19/2010CA2390526C Sequence specific dna recombination in eukaryotic cells
10/19/2010CA2380022C Aromatic esters of camptothecins and methods to treat cancers
10/19/2010CA2379988C Enzyme catalyzed therapeutic activation
10/19/2010CA2374631C Benzene derivatives, process for their preparation and pharmaceutical compositions containing them
10/19/2010CA2362715C Quinazoline derivatives as angiogenesis inhibitors
10/19/2010CA2322860C Products containing polyphenol(s) and l-arginine to stimulate nitric oxide production
10/19/2010CA2321455C Indole-3-propionic acids, salts and esters thereof used as medicaments
10/19/2010CA2307842C Hyaluronan synthase gene and uses thereof
10/19/2010CA2214338C Use of .alpha.1l agonists for treating urinary incontinence
10/19/2010CA2193130C New streptogramins and process for preparing streptogramins by mutasynthesis
10/19/2010CA2186118C Compacted nucleic acids and their delivery to cells
10/19/2010CA2165393C Anti-bordetella acellular vaccine
10/19/2010CA2147499C Prostate-specific membrane antigen
10/15/2010WO2009126950A2 Diterpene glycosides as natural solubilizers
10/15/2010CA2758122A1 Diterpene glycosides as natural solubilizers
10/14/2010WO2010118419A2 Novel anti-aging agents and methods to identify them
10/14/2010WO2010118405A2 Compositions and methods for reducing hangover symptoms
10/14/2010WO2010118390A1 Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
10/14/2010WO2010118367A2 Antiviral pyrimidines
10/14/2010WO2010118365A1 Nanoparticle formulations and uses therof
10/14/2010WO2010118362A1 Methods and compositions for inducing physiological hypertrophy
10/14/2010WO2010118354A1 Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof
10/14/2010WO2010118347A2 O-linked glycan biosynthesis modulators
10/14/2010WO2010118339A2 Formulations of indole-3-carbinol derived antitumor agents with increased oral bioavailability
10/14/2010WO2010118334A1 Methods of treating edema related to ischemia-reperfusion
10/14/2010WO2010118330A2 Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease
10/14/2010WO2010118309A2 Inhibitors of stat3 and uses thereof
10/14/2010WO2010118306A1 Photo-activated attachment of cholesterol to polyurethane surfaces for adhesion of endothelial cells
10/14/2010WO2010118298A2 Compositions and methods for bioactive coatings to improve allograft incorporation
10/14/2010WO2010118291A2 Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
10/14/2010WO2010118286A2 Benzimidazole modulators of h1 receptor and/or ns4b protein activity
10/14/2010WO2010118285A1 Method of dissolving an oxidized polysaccharide in an aqueous solution
10/14/2010WO2010118283A1 Methods for preventing and/or treating lysosomal storage disorders
10/14/2010WO2010118282A1 Methods for preventing and/or treating degenerative disorders of the central nervous system
10/14/2010WO2010118265A1 Non-pegylated liposomal doxorubicin triple combination therapy
10/14/2010WO2010118263A1 Single-nucleotide polymorphism (snp) targeting therapies for the treatment of huntington's disease
10/14/2010WO2010118250A2 Methods and compositions of pi-3 kinase inhibitors for treating fibrosis
10/14/2010WO2010118235A1 Dna-cell conjugates
10/14/2010WO2010118232A1 Controlled-release clozapine compositions
10/14/2010WO2010118208A1 Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
10/14/2010WO2010118207A1 Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
10/14/2010WO2010118200A2 Liposomal formulations of tocopheryl amides
10/14/2010WO2010118155A1 Inhibitors of fatty acid amide hydrolase
10/14/2010WO2010118153A1 Controlling drug transport and current in iontophoretic onychomycosis treatment
10/14/2010WO2010118063A2 Therapeutic compositions and related methods of use
10/14/2010WO2010118055A1 Inhibitors of cognitive decline
10/14/2010WO2010118046A1 Inhibitors of bacterial type iii secretion system
10/14/2010WO2010118028A1 Method of treating and preventing neuro-olfactory triggered or aggravated illnesses or related conditions
10/14/2010WO2010118025A1 Progesterone antagonists spiro condensed in position 17 with a difluoromethylene- substituted perhydrofurane group
10/14/2010WO2010118015A1 Control of concentric tubing direction
10/14/2010WO2010118013A1 Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
10/14/2010WO2010118010A1 Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
10/14/2010WO2010118006A1 (2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer
10/14/2010WO2010117996A1 Prolonged duration local anesthesia with minimal toxicity
10/14/2010WO2010117977A1 Hepatitis c virus inhibitors
10/14/2010WO2010117974A2 Hiv-resistant stem cells and uses thereof
10/14/2010WO2010117943A1 Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
10/14/2010WO2010117941A1 Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
10/14/2010WO2010117939A1 Hcv inhibitor and therapeutic agent combinations
10/14/2010WO2010117936A1 Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
10/14/2010WO2010117935A1 Compounds and methods for antiviral treatment
10/14/2010WO2010117932A1 Indole derivatives and methods for antiviral treatment
10/14/2010WO2010117931A1 Method of treatment based on polymorphisms of the kcnq1 gene
10/14/2010WO2010117926A1 Substituted triazolopyridines and analogs thereof
10/14/2010WO2010117860A2 Microrna signature to predict prognosis in heart failure
10/14/2010WO2010117829A2 Differentially expressed micrornas as biomarkers for the diagnosis and treatment of sjögren's syndrome
10/14/2010WO2010117800A2 Shh regulation and methods thereof
10/14/2010WO2010117787A2 Inhibiting eph b-3 kinase
10/14/2010WO2010117756A2 Substituted benzimidazole pharmaceutical formulations
10/14/2010WO2010117738A2 Solid state forms of sitagliptin salts
10/14/2010WO2010117727A2 Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
10/14/2010WO2010117704A1 Hepatitis c virus inhibitors
10/14/2010WO2010117662A1 Modulators of s1p and methods of making and using
10/14/2010WO2010117639A2 Inhibition of prostglandin e2 receptors for the treatment of endometriosis
10/14/2010WO2010117635A1 Hepatitis c virus inhibitors
10/14/2010WO2010117633A1 Treatment regimen utilizing neratinib for breast cancer
1 ... 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 ... 7860